PLT Health Solutions has created a new ingredient called cellflo6 which will help with sports performance and other health benefits.
A recent press release1 revealed PLT Health Solutions has introduced a new ingredient called cellflo6. The newest item in the company’s portfolio is aiming to help improve overall health benefits, sports performance, and increased energy.1 As mentioned in the press release, “the ingredient is a patented, gallate-enhanced oligomer extract sourced from green tea (Camellia sinensis).” It can also be found in several types of men’s health formulations such as, pre-workout, energy, and recovery products.
Brett Bernier, director of sports and active nutrition for PLT Health Solutions explained how, “Today’s consumers are looking for a more impactful experience and performance benefits from a wide range of delivery systems. The industry is starting to recognize the unique benefits of cellflo6 and what it can bring to a product formulation. It is known to help support improved endurance, faster recovery, enhanced blood flow, and energy. We’re very excited to be working with Cardio6 Management to further develop and commercialize this unique technology." 1
The patented ingredient was clinically studied and is part of US Patent No.: US 11,766,422 B2 which is a patent on galloylated procyanidins used for improved blood flow and the treatment of endovascular dysfunction.1
“Cellflo6 is a new and exciting ingredient, that people respond to because it is highly experiential. It is easy to formulate since it is water-soluble, presents no taste issues and has a low inclusion rate. We are just beginning to understand its market potential and we are excited to be working with PLT Health Solutions to significantly expand the reach of cellflo6 around the world,” Matt Nickerson Co-inventor of cellflo6®, said Matt Nickerson, co-inventor of cellflo6.
To learn more about cellflo6®, please visit www.plthealth.com/cellflo6 or stop by PLT Health Solutions Booth# 4655 at SupplySide West 2024 in Las Vegas, Nevada, between October 30-31, 2024.
Reference
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.